Best Healthcare Companies in New Haven, United States
The 31 best Healthcare companies in New Haven, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biohaven.
Ranked: Best Healthcare companies in New Haven
| # | Company | Last round | Disclosed funding | Stage | Employees | Founded | Founder | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | A Touch of Love Homecare Provider of elderly companionship care services | — | — | Unfunded | 10 | 2018 | — | — |
| 2 | AandB Homehealth Solutions A & B Homecare Solutions believes that every individual has the right to remain independent in their… | — | — | — | 56 | 2003 | — | — |
| 3 | Advanced Diagnostic Pain Treatment Centers Chain of pain clinics | — | — | Unfunded | 11 | 1999 | — | — |
| 4 | APNH A Place to Nourish your Health Formally known as AIDS Project New Haven, our vision is a community where everyone has access to high… | — | — | — | 35 | — | — | — |
| 5 | Community First Health Centers Since 1975, Community First Health Centers (formerly Downriver Community Services) has provided primary care… | — | — | — | 44 | 1975 | — | — |
| 6 | Haskins Laboratories Haskins Laboratories is an independent research institute with a primary focus on the biological bases for… | — | — | — | 84 | — | — | — |
| 7 | Levy Dental Group Standalone dental clinic | — | — | Deadpooled | — | 1964 | Jennifer You CEO | — |
| 8 | mActivity Family fitness center | — | — | Funding Raised | — | 2015 | Pablo Perez Co-Founder | — |
Top 12 Healthcare companies in New Haven
#1
Funding Raised · New Haven, Connecticut · founded 1971 · 246 employees$192.5Mraised▾
Fair Haven Community Health Care is a Health Center Program grantee that offers integrated primary care, behavioral health, midwifery, and dental referrals. They also offer remote care via secure HIPAA compliant audio, video, and chat.
- 2025Grant (prize money)$2.8M
- May 2025Grant (prize money)$61.5K
- May 2025Grant (prize money)$36.3M
- Apr 2025Grant (prize money)$1.6M
#2
Public · New Haven, Connecticut · founded 2022 · 202 employees$250Mraised▾
Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases. The company leverages its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia and myostatin inhibition for neuromuscular diseases.
- Apr 2025Post IPO$250M
#3
Seed · New Haven, Connecticut · founded 2021 · 3 employees$12.3Mraised▾
Provider of contract based drugs development services for biopharma sector
- Sep 2025Seed$14.5M
- Oct 2024Seed$12.3M
#4
Seed · New Haven, Connecticut · founded 2017 · 4 employees$743Kraised▾
Provider of senior care and stroke monitoring services
- Jun 2025Grant (prize money)$500K
- May 2025Grant (prize money)$1.5M
- Mar 2023Seed$743K
- Sep 2019Grant (prize money)$257K
#5
Series A · New Haven, Connecticut · founded 2022 · 8 employees$18.6Mraised▾
Provider of post traumatic stress disorder care services
- Oct 2024Series A$14.5M
- Nov 2023Seed$4.1M
#6
Acquired · New Haven, Connecticut · founded 2021 · 58 employees$42.7Mraised▾
Provider of mental healthcare services. It specializes in suicide care, as well as offering teletherapy and psychiatry services for individuals living with mental health conditions such as depression, anxiety, obsessive-compulsive disorder, and trauma support services.
- Jan 2024Series A$22.5M
- Dec 2022Series A$11.8M
- 2022Seed$8.4M
#7
Early Stage · New Haven, Connecticut · founded 2002 · 17 employees$60Kraised▾
Provider of clinical development services
- Sep 2025Grant (prize money)$291.9K
- Aug 2011Grant (prize money)—
- Aug 2011Grant (prize money)$718.3K
- Jun 2008Grant (prize money)$1.4M
#8
Series A · New Haven, Connecticut · founded 2020 · 6 employees$10Mraised▾
CRO offering chemical proteomics services for preclinical development of drug
- Feb 2024Series A$10M
#9
Acquired · New Haven, Connecticut · founded 2014 · 932 employees$84.1Mraised▾
Developer of therapies targeting neurological and neuropsychiatric diseases. The company's drug pipeline includes BHV-0223, a novel formulation of a glutamate-modulating agent, being developed under the FDA. It also provides a BHV-4157glutamate modulator for the treatment of spinocerebellar ataxia (SCA), SHV-5000i targeting NMDA receptor antagonism for post-traumatic stress disorder, and treatment-resistant depression.
- Mar 2017Series C—
- Nov 2016Series C$80M
- Aug 2015Series A$4.1M
#10
Series B · New Haven, Connecticut · founded 2008 · 38 employees$19Mraised▾
Innovative prescription drugs using safe, established ingredients for unmet medical needs. This pharmaceutical company develops prescription drugs leveraging well-established and GRAS active pharmaceutical ingredients. Focusing on compounds with proven safety records, they create innovative and effective treatments addressing unmet medical needs. This approach streamlines drug development, ensuring rapid access to advanced therapies. They aim to set new standards in the pharmaceutical industry with innovative formulations and patient-centered care. By utilizing active ingredients with proven safety profiles, the company minimizes regulatory hurdles while accelerating the delivery of effective, high-quality treatments to patients. This strategy enables the company to bring advanced therapies to market more efficiently, improving patient outcomes while optimizing healthcare solutions.
- Aug 2016Series B$602.2K
- Oct 2015Venture Debt$6.3M
- Oct 2014Series B$11.8M
- Apr 2013Venture Debt$2M
#11
Acquired · New Haven, Connecticut · founded 2000 · 161 employees$8.8Mraised▾
Molecular NeuroImaging (MNI) is a neuroimaging services company specialising in the efficient application of PET and SPECT biomarkers in drug development and clinical research for neurodegenerative and neuropsychiatric disorders. The company offer services such as radioligand development and manufacturing, design and implementation of Imaging Studies in Phase 1 to Phase 4 clinical trials, and customised clinical imaging site coordination and management in multi-site core imaging studies and quantitative image analysis services. The company uses investigational radiotracers in combination with quantitative imaging outcome measures to study the mechanism and progression of disease. The company claims to have expertise in studying and developing biomarkers based on radiochemistry for 22 CNS targets including GABA, Beta-Amyloid Proteins, Cholinergic transporters and others. The company claims to have expertise in conducting molecular imaging studies in brain diseases including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, post-traumatic stress disorder, traumatic brain injury, Huntington’s disease, Down's syndrome, neuropsychiatric conditions and other human diseases.
- Sep 2014Grant (prize money)$3M
- Oct 2011Grant (prize money)$925.5K
- Aug 2009Grant (prize money)$533.8K
- Feb 2009Grant (prize money)$500K
#12
Deadpooled · New Haven, Connecticut · founded 2012 · 5 employees$800Kraised▾
Eli Nutrition develops an antacid called Tummyzen, which is a zinc-based over-the-counter acid reducer. Received seed funding from the YEI Innovation Fund, set up by the Yale Entrepreneurial Institute. The product is expected to be launched in the 2nd half of 2016.
- Aug 2016Seed$250K
- Dec 2015Seed$420K
- Aug 2015Seed$30K
- Mar 2015Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.